You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

936 Results
Document
Apr 2019
Document
Apr 2019
Document
Apr 2019
Document
Apr 2019
Guidelines and Advice
Status: Current
ID: GL 5-3ORG
Version: 2
Apr 2019
Document
May 2019
Document
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
iMAtinib,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Document
May 2019
Blog post
A quick glance at cancer statistics can be quite sobering: Nearly one out of every two people in Ontario will develop cancer in their lifetime, and...
Jun 2019
Document
Jun 2019
Document
Jun 2019

Pages